Recent research highlights a lack of demographic transparency in FDA-authorized artificial intelligence (AI) devices for Alzheimer's disease and related dementias (ADRD). Investigators assessed 24 devices approved between January 2015 and December 2024, finding that fewer than half disclosing demographic details such as age, sex, or race in their training data. The limited availability of representative datasets raises concerns about equitable clinical applications and risks perpetuating disparities in ADRD care, emphasizing the need for improved data transparency.

Source: JAMA